Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 7/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.39 |
| ▸ | DCAF1 | Q9Y4B6 | 3/20 | 0.39 |
| ▸ | OGT | O15294 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841455 | 0.93 | CTSA (0.44) | CTSAFFAR1DCAF1OGTALDH1A1 | |
| SCHEMBL17841456 | 0.93 | CTSA (0.44) | CTSAFFAR1DCAF1OGTALDH1A1 | |
| SCHEMBL20546129 | 0.88 | CTSA (0.42) | CTSAFFAR1SUCNR1 | |
| SCHEMBL30671391 | 0.86 | MAPT (0.43) | CTSAFFAR1MMEL1MMEDCAF1 | |
| SCHEMBL20545835 | 0.85 | HSD17B1 (0.38) | CTSAFFAR1 | |
| SCHEMBL20546005 | 0.84 | CTSA (0.36) | CTSA | |
| SCHEMBL20545785 | 0.82 | FFAR1 (0.45) | CTSAFFAR1 | |
| SCHEMBL24036979 | 0.81 | WDR5 (0.43) | DCAF1ALDH1A1HPGD | |
| SCHEMBL25753673 | 0.81 | WDR5 (0.43) | DCAF1ALDH1A1HPGD | |
| SCHEMBL22691186 | 0.81 | CYP26A1 (0.44) | CTSAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885FFAR1 37/4885MMEL1 3524/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885FFAR1 37/4885MMEL1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.